Navigation Links
Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011
Date:10/27/2011

of central nervous system conditions.  Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.  The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)

ADASUVE (Staccato loxapine) is Alexza's lead program, which is being developed for the acute treatment of agitation in adults with schizophrenia or bipolar disorder.  Alexza completed and announced positive results from both of its Phase 3 clinical trials and initially submitted the ADASUVE NDA in December 2009.  In October 2010, the Company received a Complete Response Letter from the FDA regarding the application.  The Company completed an end-of-review meeting with the FDA in December 2010 and a Risk Evaluation and Mitigation Strategy (REMS) guidance meeting with the FDA in April 2011.  The ADASUVE NDA was resubmitted on August 4, 2011 and has a Prescription Drug User Fee Act (PDUFA) goal date of February 4, 2012.  The ADASUVE NDA will be presented to an advisory committee on December 12, 2011.

In October 2011, the Company established a commercial partnership for ADASUVE with Grupo Ferrer International, S.A.  Grupo Ferrer is a leading pharmaceutical company in Europe with extensive operations in the Americas, and is Alexza's partner in the commercialization of ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.  Alexza filed its ADASUVE Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in October 2011.  

For mo
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... March 26, 2015  Becton, Dickinson and Company (NYSE: ... commence offers to exchange all validly tendered and accepted ... a wholly owned subsidiary of BD, for notes to ... below. A Registration Statement on Form S-4 (the "Registration ... was filed with the Securities and Exchange Commission ("SEC") ...
(Date:3/26/2015)... , 26. März 2015  Die ... wird vom 1. April 2015 an Zulassungsanträge für ... abgebenden Apotheken annehmen. Seit dem Start des ... Verband über 275 .pharmacy-Domainnamen zugelassen, die für ... Zeiten beantragt wurden. Die NABP startete .pharmacy ...
(Date:3/26/2015)... -- Gelesis , a clinical stage biotechnology ... to induce weight loss and improve glycemic control, ... of shares of convertible preferred stock for gross ... of approximately $4 million of outstanding convertible promissory ... to support the continued clinical development of its ...
Breaking Medicine Technology:Becton, Dickinson and Company to Commence Exchange Offers 2Becton, Dickinson and Company to Commence Exchange Offers 3Becton, Dickinson and Company to Commence Exchange Offers 4Becton, Dickinson and Company to Commence Exchange Offers 5Alle abgebenden Apotheken berechtigt, um ab dem 1. April 2015 .Pharmacy-Domainnamen zu beantragen 2Gelesis Closes $22M Equity Financing 2Gelesis Closes $22M Equity Financing 3
(Date:3/26/2015)... FL (PRWEB) March 26, 2015 ... the nation’s leading innovative specialty pharmacies, announces the ... position of Vice President of Pharmaceutical Relations. In ... beneficial connections with our pharmaceuticals partners and providing ... in support of BioPlus’ expansion. , “Over ...
(Date:3/26/2015)... In the key developed markets, the hypertension ... is set to decrease through 2020 at a negative CAGR ... expected up to 2017 at a 2.6% CAGR and a ... to the surging penetration of fixed-dose combination drugs like Azor, ... Benicar HCT, and Tekamlo), a hike in the prevalence population ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 Leading ... brand-new, state-of-the-art company website: http://www.metabolicnutrition.com . ... revamped website creates a user-friendly experience for consumers ... , The new, enhanced Metabolic Nutrition website ... about the company’s diverse line of products, conveniently ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 Zane Benefits, ... businesses, announced a new eBook, “The Comprehensive Guide To ... eBook, interviewing is the most important aspect of the ... they are hiring the right way, possibly resulting in ... be an arduous undertaking, yet it’s essential to the ...
(Date:3/26/2015)... 26, 2015 LinkToBanking, a Preferred ... names Tom Fleming as Chairman of the Board ... effective immediately. With their combined knowledge and ... industry, Mr. Fleming and Mr. Casares will provide ... to cannabis related businesses. , About Tom Fleming, ...
Breaking Medicine News(10 mins):Health News:BioPlus Specialty Pharmacy Expands Executive Team with New Position, Naming Sharon Ferrer as Vice President of Pharmaceutical Relations 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 3Health News:Metabolic Nutrition Launches Sleek New Website with New Features and Enhanced Consumer Information 2Health News:Zane Benefits Announces: New eBook: The Comprehensive Guide To Interviewing For Your Small Business 2Health News:Tom Fleming named Chairman of the Board and Robert Casares as Vice-Chairman of the Board of LinkToBanking 2Health News:Tom Fleming named Chairman of the Board and Robert Casares as Vice-Chairman of the Board of LinkToBanking 3
... toll was so overwhelming that steam shovels were brought in ... trains commandeered to transport dead soldiers and priests could be ... threat of another flu pandemic looming in the not too ... preparations for it mortuary specialists are once more faced with ...
... babies much before the full term are administered steroids. ... the University of Adelaide , has found that subjecting ... babies by reducing potential breathing difficulties during delivery. ... babies from the Adelaide Women's and Children's Hospital. Research ...
... to introduce a system in which the GPs would be graded ... government to vote in favor for the new scheme of grading ... According to this the surgeries were to be inspected by doctors, ... one to three. It was a modification of the accreditation scheme. ...
... which is already running in a loss would have to pay ... are not in a position // to fulfil the commitment to ... health services. ,The trusts in the south of England ... ?20bn scheme under a deal with Japanese firm Fujitsu. But the ...
... Cheltenham Science Festival that it plans to send a ... //a research into the effects of low oxygen levels, ... for Aviation, Space and Extreme Environment Medicine at the ... will be conducting the research along with researchers around ...
... In a breakthrough move against HIV drug resistance, scientists have now ... that is the first in a new class of HIV drug ... Caspsid, a key viral protein from its precursor protein,this group of ... acid, and interferes with the production of the capsid conical ...
Cached Medicine News:Health News:What to do with the Dead if a Flu Outbreak Happens? 2Health News:Already Short Staffed And In Deficit NHS Fails To Supply Staff For IT Project 2Health News:Mount Everest to be Site of Research into Hypoxia 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: